Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EBITDA (2020 - 2025)

Historic EBITDA for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$9.6 million.

  • RxSight's EBITDA fell 6913.49% to -$9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.2 million, marking a year-over-year decrease of 2018.4%. This contributed to the annual value of -$27.3 million for FY2024, which is 4376.52% up from last year.
  • According to the latest figures from Q3 2025, RxSight's EBITDA is -$9.6 million, which was down 6913.49% from -$11.9 million recorded in Q2 2025.
  • In the past 5 years, RxSight's EBITDA registered a high of -$5.7 million during Q3 2024, and its lowest value of -$17.7 million during Q1 2022.
  • Over the past 5 years, RxSight's median EBITDA value was -$12.4 million (recorded in 2023), while the average stood at -$11.6 million.
  • Per our database at Business Quant, RxSight's EBITDA tumbled by 15986.84% in 2021 and then surged by 5569.66% in 2024.
  • Over the past 5 years, RxSight's EBITDA (Quarter) stood at -$15.7 million in 2021, then rose by 1.12% to -$15.6 million in 2022, then soared by 41.4% to -$9.1 million in 2023, then skyrocketed by 31.01% to -$6.3 million in 2024, then tumbled by 53.17% to -$9.6 million in 2025.
  • Its EBITDA was -$9.6 million in Q3 2025, compared to -$11.9 million in Q2 2025 and -$8.3 million in Q1 2025.